CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
TDF2 study of pre-exposure prophylaxis (PrEP) among heterosexual men and women in Botswana : key facts
-
8/26/11
Details:
-
Corporate Authors:
-
Description:Daily oral PrEP with a tablet containing tenofovir disoproxil fumarate and emtricitabine (TDF/FTC, known by the brand name Truvada®) was found to reduce the risk of acquiring HIV infection by roughly 63 percent in the study population overall.
In addition, researchers conducted a separate analysis to better understand the level of efficacy among trial participants believed to be taking study medications. This analysis excludes any HIV infections that occurred more than 30 days1 after a participant’s last reported drug dose, because those individuals could not have been taking study pills at the time of infection. These results indicate that TDF/FTC reduced the risk of HIV infection by 78 percent.
-
Subjects:
-
Document Type:
-
Genre:
-
Place as Subject:
-
Pages in Document:4 numbered pages
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
[PDF-98.02 KB]
